Your session is about to expire
← Back to Search
Study Summary
This trial is testing a drug to see if it can improve overall survival for people with stage IIIa AL amyloidosis, a disease where abnormal proteins build up in organs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Patients must be at least 18 years of ageMy diagnosis of amyloidosis was confirmed with specific tests on tissue samples.I have POEMS syndrome or multiple myeloma with specific symptoms or test results.My condition is not AL amyloidosis.My first treatment for my blood disorder will be with CyBorD.Your blood tests show certain levels that indicate the disease is active.My condition is stage IIIa AL amyloidosis with NT-proBNP > 650 ng/L.I have been treated for AL amyloidosis or multiple myeloma, but only briefly used a specific treatment regimen.I am a man who is either surgically sterile or will use effective birth control during and up to 5 or 12 months after the study, depending on my treatment.I have heart issues due to AL amyloidosis, confirmed by tests.My blood pressure is very low or drops significantly when I stand up, despite treatment.
- Group 1: CAEL-101 combined with SoC plasma cell dyscrasia
- Group 2: Placebo combined with SoC plasma cell dyscrasia
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there other similar testing procedures for CAEL-101?
"Right now, there are over 1300 trials researching CAEL-101 with almost 300 of those in Phase 3. Most of the testing for CAEL-101 is happening in Philadelphia, but there are 43000+ locations running studies related to CAEL-101."
Does this trial have a lot of locations in North America?
"67 medical centres across the United States are participating in this clinical trial, including renowned institutions such as Indiana University School of Medicine Amyloid Research and Treatment, Medical College of Wisconsin, and Memorial Sloan Kettering Cancer Center."
What are the conditions that CAEL-101 is designed to address?
"Oftentimes, CAEL-101 is used to ameliorate synovitis. Additionally, it has shown efficacy in treating ophthalmia, cancerous growths in the lungs, and branch retinal vein occlusion."
Has CAEL-101 received permission from the FDA to be used?
"CAEL-101 is safe according to our team's estimation. This is a Phase 3 trial, which means that efficacy has been supported by some data and safety has multiple rounds of supportive data."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger